Push forward LC-MS-based therapeutic drug monitoring and pharmacometabolomics for anti-tuberculosis precision dosing and comprehensive clinical management.
10.1016/j.jpha.2023.09.009
- Author:
Nguyen Quang THU
1
;
Nguyen Tran Nam TIEN
1
;
Nguyen Thi Hai YEN
1
;
Thuc-Huy DUONG
2
;
Nguyen Phuoc LONG
1
;
Huy Truong NGUYEN
3
Author Information
1. Department of Pharmacology and PharmacoGenomics Research Center, Inje University College of Medicine, Busan, 47392, Republic of Korea.
2. Department of Chemistry, University of Education, Ho Chi Minh City, 700000, Viet Nam.
3. Faculty of Pharmacy, Ton Duc Thang University, Ho Chi Minh City, 700000, Viet Nam.
- Publication Type:Review
- Keywords:
LC-MS;
MIPD;
Pharmacometabolomics;
Precision medicine;
Therapeutic drug monitoring;
Tuberculosis
- From:
Journal of Pharmaceutical Analysis
2024;14(1):16-38
- CountryChina
- Language:English
-
Abstract:
The spread of tuberculosis (TB), especially multidrug-resistant TB and extensively drug-resistant TB, has strongly motivated the research and development of new anti-TB drugs. New strategies to facilitate drug combinations, including pharmacokinetics-guided dose optimization and toxicology studies of first- and second-line anti-TB drugs have also been introduced and recommended. Liquid chromatography-mass spectrometry (LC-MS) has arguably become the gold standard in the analysis of both endo- and exo-genous compounds. This technique has been applied successfully not only for therapeutic drug monitoring (TDM) but also for pharmacometabolomics analysis. TDM improves the effectiveness of treatment, reduces adverse drug reactions, and the likelihood of drug resistance development in TB patients by determining dosage regimens that produce concentrations within the therapeutic target window. Based on TDM, the dose would be optimized individually to achieve favorable outcomes. Pharmacometabolomics is essential in generating and validating hypotheses regarding the metabolism of anti-TB drugs, aiding in the discovery of potential biomarkers for TB diagnostics, treatment monitoring, and outcome evaluation. This article highlighted the current progresses in TDM of anti-TB drugs based on LC-MS bioassay in the last two decades. Besides, we discussed the advantages and disadvantages of this technique in practical use. The pressing need for non-invasive sampling approaches and stability studies of anti-TB drugs was highlighted. Lastly, we provided perspectives on the prospects of combining LC-MS-based TDM and pharmacometabolomics with other advanced strategies (pharmacometrics, drug and vaccine developments, machine learning/artificial intelligence, among others) to encapsulate in an all-inclusive approach to improve treatment outcomes of TB patients.
